NCT07157423View on ClinicalTrials.gov

A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India

PHASE4RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

March 26, 2027

Study Completion Date

March 26, 2027

Conditions
Severe Postpartum Haemorrhage
Interventions
DRUG

Eptacog alfa (NovoSeven)

Participants will receive single dose of intravenous bolus injection of eptacog alfa (NovoSeven)

Trial Locations (8)

110029

NOT_YET_RECRUITING

All India Institute of Medical Sciences_New Dehli, New Delhi

160012

NOT_YET_RECRUITING

Post Graduate Institute of Medical Education & Research_Chandigarh, Chandigarh

302004

NOT_YET_RECRUITING

SMS Hospital, Jaipur

400012

NOT_YET_RECRUITING

Seth GS Medical College & KEM Hospital, Mumbai

590010

RECRUITING

KLE Belgum, Belagavi

NOT_YET_RECRUITING

KLE Belgum, Belagavi

673008

RECRUITING

Calicut Medical College, Kozhikode

NOT_YET_RECRUITING

Calicut Medical College, Kozhikode

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY